| 188RNL-BAM | // NONE | phase-2 | Plus Therapeutics [PSTV] | // UNMAPPED_TARGET |
| ALT-801 | Pemvidutide | phase-3 | Altimmune [ALT] | GLP1R |
| ARQ-151 | Roflumilast | approved | Arcutis Biotherapeutics [ARQT] | PDE4 |
| ARQ-234 | // NONE | NDA | Arcutis Biotherapeutics [ARQT] | // UNMAPPED_TARGET |
| ATNM-400 | // NONE | phase-1 | Actinium Pharmaceuticals [ATNM] | // UNMAPPED_TARGET |
| BBO-10203 | // NONE | phase-1 | BridgeBio Oncology Therapeutics [BBOT] | PI3Kα |
| BBO-11818 | // NONE | phase-1 | BridgeBio Oncology Therapeutics [BBOT] | KRAS |
| BBO-8520 | // NONE | phase-1 | BridgeBio Oncology Therapeutics [BBOT] | KRAS |
| BMF-219 | Icovamenib | phase-2 | Biomea Fusion [BMEA] | GLP1R |
| BMF-650 | // NONE | phase-2 | Biomea Fusion [BMEA] | GLP1R |
| CFT7455 | Cemsidomide | phase-2 | C4 Therapeutics [CCCC] | IKZF1/3 |
| CFT8919 | // NONE | phase-1 | C4 Therapeutics [CCCC] | EGFR |
| CX-2051 | Varseta-M | phase-1 | CytomX Therapeutics [CTMX] | // UNMAPPED_TARGET |
| CX-801 | // NONE | phase-1 | CytomX Therapeutics [CTMX] | // UNMAPPED_TARGET |
| CX-908 | // NONE | preclinical | CytomX Therapeutics [CTMX] | // UNMAPPED_TARGET |
| Iomab-ACT | // NONE | phase-1 | Actinium Pharmaceuticals [ATNM] | // UNMAPPED_TARGET |
| Iomab-B | // NONE | phase-3 | Actinium Pharmaceuticals [ATNM] | // UNMAPPED_TARGET |
| Lintuzumab-Ac225 | Actimab-A | phase-3 | Actinium Pharmaceuticals [ATNM] | // UNMAPPED_TARGET |
| MRT-2359 | // NONE | phase-1 | Monte Rosa Therapeutics [GLUE] | // UNMAPPED_TARGET |
| MRT-6160 | // NONE | phase-1 | Monte Rosa Therapeutics [GLUE] | // UNMAPPED_TARGET |
| MRT-8102 | // NONE | phase-1 | Monte Rosa Therapeutics [GLUE] | // UNMAPPED_TARGET |
| MT-401 | Zedenoleucel | phase-1 | Marker Therapeutics [MRKR] | // UNMAPPED_TARGET |
| MT-601 | Neldaleucel | phase-1 | Marker Therapeutics [MRKR] | // UNMAPPED_TARGET |
| RAD101 | // NONE | phase-2 | Radiopharm Theranostics [RADX] | // UNMAPPED_TARGET |
| RAD202 | // NONE | phase-1 | Radiopharm Theranostics [RADX] | HER2 |
| RAD204 | // NONE | phase-1 | Radiopharm Theranostics [RADX] | PD-L1 |
| RAD301 | // NONE | phase-1 | Radiopharm Theranostics [RADX] | // UNMAPPED_TARGET |
| RAD402 | // NONE | phase-1 | Radiopharm Theranostics [RADX] | // UNMAPPED_TARGET |
| Rhenium Re186 obisbemeda | REYOBIQ | phase-2 | Plus Therapeutics [PSTV] | // UNMAPPED_TARGET |
| RP1 | Vusolimogene oderparepvec | phase-3 | Replimune Group [REPL] | // UNMAPPED_TARGET |
| RP2 | Sturlimogene erparepvec | phase-2 | Replimune Group [REPL] | // UNMAPPED_TARGET |
| RV01 | // NONE | phase-1 | Radiopharm Theranostics [RADX] | // UNMAPPED_TARGET |
| ZN-c3 | Azenosertib | phase-3 | Zentalis Pharmaceuticals [ZNTL] | WEE1 |